Rioja, Ciguena 60, 26004, Logrono, SpainReyes Lorente, Fernando Antonanzas & Roberto Rodriguez-Ibeas AuthorsSearch for Reyes Lorente in:PubMed • Google Scholar Search for Fernando Antonanzas in:PubMed
Reyes Lorente Antoñanzas1 , Juan Luis Varona Malumbres2 , Fernando Antoñanzas Villar1 , Javier Rejas Gutiérrez3 1 Departamento de Economía y Empresa, Universidad de La Rioja, Logroño. 2
Reyes Lorente Antoñanzas1 , Juan Luis Varona Malumbres2 , Fernando Antoñanzas Villar1 , Javier Rejas Gutiérrez3 1 Departamento de Economía y Empresa, Universidad de La Rioja, Logroño. 2
Reyes Lorente Antoñanzas1 , Juan Luis Varona Malumbres2 , Fernando Antoñanzas Villar1 , Javier Rejas Gutiérrez3 1 Departamento de Economía y Empresa, Universidad de La Rioja, Logroño. 2
Prescriptions and Pharmaceutical Expenditures Fernando Antoñanzas Villar, Roberto Rodríguez-Ibeas, Carmelo A. Juárez-Castelló y Ma Reyes Lorente Antoñanzas Departamento de Economía y Empresa
Prescriptions and Pharmaceutical Expenditures Fernando Antoñanzas Villar, Roberto Rodríguez-Ibeas, Carmelo A. Juárez-Castelló y Ma Reyes Lorente Antoñanzas Departamento de Economía y Empresa
Background This study aimed to assess the costs and clinical benefits of the 13-valent pneumococcal conjugate vaccine (PCV13) administered annually to the 65-year-old cohort in Spain versus the alternative of not vaccinating patients and treating them only when infected. Methods Cases of pneumococcal disease avoided were calculated through a dynamic model based on the work of...
This study aimed to assess the costs and clinical benefits of the 13-valent pneumococcal conjugate vaccine (PCV13) administered annually to the 65-year-old cohort in Spain versus the alternative of not vaccinating patients and treating them only when infected. Cases of pneumococcal disease avoided were calculated through a dynamic model based on the work of Anderson and May (1999...